Europe Platelet Rich Plasma Market, Product Type (Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others), By Origin (Autologous, Allogeneic/Homologues), By Application (Orthopaedics, Cosmetic Surgery and Dermatology, Neurosurgery, Cardiothoracic Surgery, General Surgery, Urology, Others), and By Country (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Platelet-rich plasma consists of two elements: plasma, or the liquid portion of blood, and platelets, a type of blood cell that plays an important role in healing throughout the body. Platelets are well-known for their clotting abilities, but they also contain growth factors that can trigger cell reproduction and stimulate tissue regeneration or healing in the treated area. Platelet-rich plasma is simply blood that contains more platelets than normal. Autologous platelet-rich plasma (PRP) is a blood plasma concentrate enriched with platelet count above the baseline of whole blood prepared from patient’s own blood. PRP is injected directly at the site of inflamed tissue releasing growth factor which stimulates and increases number of reparative cell in patient body. Platelet rich plasma protein consists of three proteins, which acts as cell adhesive molecules that are fibrin, fibronectin, and vitronectin. PRP is used for treatment of injured tendons, ligaments, muscles and joints Increasing prevalence of musculoskeletal injuries along with increasing prevalence of knee osteoarthritis is expected to boost growth of Europe platelet-rich plasma market over the forecast period.
Market Dynamics
Increasing adoption of organic growth strategies, such as product launch by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, on February 14 2023, Royal Biologics, an orthobiologics & life science company, announced the commercial launch of BIOINCYTE PRFM, a next-generation Platelet Rich Plasma (PRP) system, which converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations and eliminates extensive contamination of red blood cells & white blood cells during the formulation of PRP.
Key features of the study:
This report provides in-depth analysis of the Europe platelet rich plasma, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the europe platelet rich plasma based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Vivostat A/S, Estar Medical, CosmoFrance Inc., Kelly Harris Aesthetics, Arthrex, Inc., Terumo Corporation, T-Biotechnology Ltd. St., EmCyte Corporation, Johnson & Johnson Private Limited, Zimmer Biomet, PRP Concepts, ADVACARE PHARMA, Isto Biologics, Arthrex, Inc., Stryker, GLOFINN, Medira Ltd, Regen Lab SA, Estar Technologies Ltd.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global platelet rich plasma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe platelet rich plasma
Detailed Segmentation:
Europe Platelet Rich Plasma Market, By PRP Type:
Pure-PRP
Leukocyte-Rich PRP
Pure Platelet Rich Fibrin
Others
Europe Platelet Rich Plasma Market, By Origin:
Autologous
Allogeneic/Homologues
Europe Platelet Rich Plasma Market, By Application:
Orthopaedics
Cosmetic Surgery and Dermatology
Neurosurgery
Cardiothoracic Surgery
General Surgery
Urology
Others
Europe Infection Surveillance Market, By Country:
U.K.
Germany
France
Italy
Spain
Russia
Rest of Middle East
Company Profiles
Vivostat A/S*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Estar Medical
CosmoFrance Inc.
Kelly Harris Aesthetics
Arthrex, Inc.
Terumo Corporation
T-Biotechnology Ltd. St.
EmCyte Corporation
Johnson & Johnson Private Limited
Zimmer Biomet
PRP Concepts
ADVACARE PHARMA
Isto Biologics
Arthrex, Inc.
Stryker
GLOFINN
Medira Ltd
Regen Lab SA
Estar Technologies Ltd.
“*” marked represents similar segmentation in other categories in the respective section.